Long-term Outcomes After Thiotepa-based High-dose Therapy (HDT) and Autologous Hematopoietic Cell Transplantation (auto-HCT) in Non-Hodgkin Lymphoma (NHL)

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2016 Nov 29

PMID 27892948

Citations 2

Authors

N Shah

S Rauenzahn

L Veltri

S Wen

M Craig

M Hamadani

A S Kanate

A Cumpston

Affiliations

Soon will be listed here.

Citing Articles

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz A, Schoder H, Gavane S, Thoren K, Fleisher M, Yahalom J Blood. 2017; 130(20):2196-2203.

PMID: 28874350 PMC: 5691245. DOI: 10.1182/blood-2017-06-788877.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Morton L, Saber W, Baker K, Barrett A, Bhatia S, Engels E Biol Blood Marrow Transplant. 2016; 23(3):367-378.

PMID: 27634019 PMC: 5285307. DOI: 10.1016/j.bbmt.2016.09.005.

References

Omuro A, Correa D, DeAngelis L, Moskowitz C, Matasar M, Kaley T . R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015; 125(9):1403-10. PMC: 4342354. DOI: 10.1182/blood-2014-10-604561. View

van der Wall E, Beijnen J, Rodenhuis S . High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev. 1995; 21(2):105-32. DOI: 10.1016/0305-7372(95)90023-3. View

McCoy A, Smith E, Atkinson M, Baranski B, Kahl B, Juckett M . A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant. 2004; 33(1):19-24. DOI: 10.1038/sj.bmt.1704312. View

Caballero M, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L . BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997; 20(6):451-8. DOI: 10.1038/sj.bmt.1700913. View

Fenske T, Kahl B, Eickhoff J, Mitchell T, Smith E, Atkinson E . Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leuk Lymphoma. 2005; 46(10):1441-8. DOI: 10.1080/10428190500144656. View

Chen Y, Batchelor T, Li S, Hochberg E, Brezina M, Jones S . Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin.... Cancer. 2014; 121(2):226-33. PMC: 4293259. DOI: 10.1002/cncr.29023. View

Bhatt V, Vose J . Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. Hematol Oncol Clin North Am. 2014; 28(6):1073-95. DOI: 10.1016/j.hoc.2014.08.015. View

Wheeler C, Antin J, Churchill W, Come S, Smith B, Bubley G . Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990; 8(4):648-56. DOI: 10.1200/JCO.1990.8.4.648. View

Sellner L, Boumendil A, Finel H, Choquet S, De Rosa G, Falzetti F . Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2015; 51(2):212-218. DOI: 10.1038/bmt.2015.273. View

10.

Schiffman K, Buckner C, Maziarz R, Maloney D, Appelbaum F, Press O . High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant. 1998; 3(5):261-6. View

11.

Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R . Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003; 32(3):279-85. DOI: 10.1038/sj.bmt.1704110. View

12.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G . High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006; 24(24):3865-70. DOI: 10.1200/JCO.2006.06.2117. View

13.

Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O . High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. Hematology. 2012; 17(1):23-7. DOI: 10.1179/102453312X13221316477534. View

14.

Waheed F, Kancherla R, Seiter K, Liu D, Qureshi Z, Hoang A . High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma. 2004; 45(11):2253-9. DOI: 10.1080/10428190410001723250. View

15.

Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S . High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation. Bone Marrow Transplant. 2004; 34(9):781-6. DOI: 10.1038/sj.bmt.1704672. View